Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Glioblastoma: early-phase trial registry
29 of 63 indexed Recurrent Glioblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #222 of 28,707 conditions by registered trial count.
63 US clinical trials · 29 currently recruiting · #222 of 28,707 conditions by registered trial count
Recurrent Glioblastoma: 63 US clinical trials tracked, 29 recruiting.
Recurrent Glioblastoma is the subject of 63 registered US clinical trials on ClinicalTrials.gov, 29 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 54 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition recurrent-glioblastoma
OPEN 29 | RECR 46% | LATE 2 | EARLY 54 | RANK #222 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Chronic Pain (46% recruiting · 302 trials)
Recurrent Glioblastoma lists 29 open slots (46% of 63 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Glioblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Glioblastoma is recruiting above its size-band peers.
29 of 63 indexed trials (46%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Recurrent Glioblastoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 7 of 63 trials (11.1%). 39 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Glioblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 63 trials that report a genuine target (sentinel values excluded). 54 of those (85.7%) plan for fewer than 100 participants.
-
Recurrent Glioblastoma research is mostly interventional.
61 interventional and 2 observational studies make up this index (96.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
63 total, page 2 of 2
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
NCT01609790
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Celldex Therapeutics
NCT01498328
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT01849146
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03914742
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Northwestern University
NCT02794883
Feasibility of Individualized Therapy for Recurrent Glioblastoma
Jennifer Clarke
NCT03681028
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
NCT02101905
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology
NCT04479241
ASP8374 + Cemiplimab in Recurrent Glioma
Dana-Farber Cancer Institute
NCT04826393
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Case Comprehensive Cancer Center
NCT04051606
Mathematical Model-Adapted Radiation In Glioblastoma
Dana-Farber Cancer Institute
NCT03557372
BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
Seema Nagpal
NCT03020602
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
M.D. Anderson Cancer Center
NCT01904123
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 17 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Glioblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Glioblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Glioblastoma page
63 registered trials, 29 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 29 Recurrent Glioblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Glioblastoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Glioblastoma condition card totals 63 registered trials; most-linked intervention Temozolomide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.